Response Adapted Neoadjuvant Therapy in Gastric Cancer (RANT-GC) - a Phase 1b Feasibility Trial
Details
The purpose of this study is to see how safe and feasible it is to use a response-guided treatment approach before surgery (called neoadjuvant treatment) for patients with adenocarcinoma of the stomach or gastroesophageal (LGEA). This means the way treatment is given may be adjusted based on how your cancer is responding by measuring your tumor utilizing imaging, such as Computed Tomography (CT) Scans, or Magnetic Resonance Imaging (MRI) or looking at blood samples for tumor markers in such as carcinoembryonic antigen (CEA) and Carbohydrate antigen 19-9 (CA19-9). We are looking at how well this treatment process works and whether you and others are able to complete it as planned. We will also collect information about your health, how the treatment affects your body, and details from tests on your tissue and cells.
Eligibility
You can join if...
You can participate in this study if you satisfy the following criteria:
Are at least 18 years of age or older
Confirmed diagnosis of adenocarcinoma (cancer) of the stomach or gastroesophageal junction (GEA)
Stage IB, II or Stage III GEA eligible for (neo)adjuvant chemotherapy for up to 6 months
You cannot participate in this study if you have any of the following criteria:
Are receiving any other investigational agents
Any active infection or other cancers
Pregnant or nursing